Statin Efficacy in the Treatment of Hepatitis C Genotype I



Shavakhi A¹ ; Minakari M¹ ; Bighamian A¹ ; Sadeghian S¹ ; Shavakhi S² ; Khamisi N¹ ; Khodadustan M¹ ; Talebi M¹ ; Ataei B² Show Affiliations
Source: Journal of Research in Medical Sciences Published:2014

Abstract

Background: Lipid metabolism is one of the hepatitis C virus (HCV) life cycle steps. Statins can reduce cholesterol level and fi nally can decrease HCV replication. Th us, we assessed the eff ect of Statins in combination with standard antiviral treatment on hyperlipidemic genotype I HCV infected patients. Materials and Methods: Th is study was a prospective clinical trial. 40 patients were selected from those referred to educational and Th erapeutic Centers of Isfahan University of Medical Sciences from 2009 to 2010 with confi rmed HCV viremia. All patients received Peg-interferon-a2a and ribavirin. 20 hyperlipidemic Patients received 20 mg atorvastatin nightly for 3 months and placebo was prescribed for 20 normolipidemic HCV infected patients as a control group. Liver enzymes and complete blood count were checked monthly and thyroid stimulating hormone was checked every 3 months. We also performed quantitative HCV-ribonucleic acid (RNA) test in 12th week of therapy, at the end of treatment and 6 months after therapy for all samples. Results: We didn't fi nd any signifi cant diff erences in the mean of HCV-RNA numbers between statin and placebo groups in 12th week of treatment, in the end of treatment and 6 months after treatment (P > 0.05). Conclusion: Atorvastatin has no eff ect on the mean of HCV viral load when we added it to standard treatment for hepatitis C infection. Further studies are necessary to examine the possible antiviral properties of statins and their potential role as adjuncts to standard HCV therapy.